Genome Editing and Engineering
-10%
portes grátis
Genome Editing and Engineering
From TALENs, ZFNs and CRISPRs to Molecular Surgery
;
Cambridge University Press
08/2018
498
Dura
Inglês
9781107170377
15 a 20 dias
Descrição não disponível.
List of contributors; Forewords; Preface; List of abbreviations; Part I. Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks: 1. Introduction to genome editing and engineering: from Talens, ZFNs and CRISPRs to molecular surgery; 2. Targeted genome editing techniques in C. elegans and other nematode species; 3. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors; 4. In vivo studies of miRNA target interactions using site-specific genome engineering; 5. Don't kill the messenger: employing genome editing to study regulatory RNA interactions; Part II. Genome Editing in Model Organisms: 6. Genome editing in the crustacean Daphnia magna using CRISPR/Cas and TALEN systems; 7. Leapfrogging: a method for targeting genome editing to the germline; 8. Genome editing with desired mutations (knock-in) by CRISPR in model organisms; 9. Genetically engineered pig models for human diseases using ZFNs, TALENs and CRISPR-Cas9; 10. Gene editing to create agricultural and biomedical swine models; 11. Generation of new model cell lines using ssODN knock-in donors and FACS-based genome editing; Part III. Technology Development and Screening: 12. CRISPR genome editing in mice; 13. Detection of insertion/deletion (indel) events after genome targeting: pros and cons of the available methods; 14. Application of TAL proteins and the CRISPR system to purification of specific genomic regions for locus-specific identification of chromatin-associated molecules; 15. Application of CRISPR for pooled, vector-based functional genomic screening in mammalian cell lines; 16. Generation and utilization of CRISPR/Cas9 screening libraries in mammalian cells; Part IV. Genome Editing in Stem Cells and Regenerative Biology: 17. Targeted genome editing using nuclease assisted vector integration; 18. Genome engineering using Sleeping Beauty transposition in vertebrates; 19. Genome editing of pluripotent stem cells; 20. Principles for targeting adult tissue stem cells to achieve durable gene and gene-editing therapies; 21. Therapeutic genome editing in human hematopoietic stem and progenitor cells; Part V. Genome Editing in Disease Biology: 22. CRISPR/Cas9-Based in vivo models of cancer; 23. Inducible CRISPR-based genome editing for the characterization of cancer genes; 24. Genome editing for retinal diseases; 25. Manipulation of long non-coding RNAs in cardiovascular disease using genome-editing technology; 26. Gene silencing, disruption and latency reactivation with RNA-based and gene editing CRISPR/Cas, ZFN and TALEN technologies for HIV-1/AIDS therapies; 27. Use of the CRISPR-Cas9 system for genome editing of immune system cells, defense against HIV-1 and cancer therapies; 28. Harnessing therapeutic potential of long non-coding RNAs in immunity; Part VI. Legal (Intelluctual Property) and Bioethical Issues of Genome Editing: 29. Patening of CRISPR-based inventions; 30. Patent, ownership, and licensing issues of CRISPR-based genome editing: impact on universities and their licensees; 31. The ethics of human genome editing; 32. Regulating human genome editing: negotiating ethical concerns through science and policy; Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
List of contributors; Forewords; Preface; List of abbreviations; Part I. Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks: 1. Introduction to genome editing and engineering: from Talens, ZFNs and CRISPRs to molecular surgery; 2. Targeted genome editing techniques in C. elegans and other nematode species; 3. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors; 4. In vivo studies of miRNA target interactions using site-specific genome engineering; 5. Don't kill the messenger: employing genome editing to study regulatory RNA interactions; Part II. Genome Editing in Model Organisms: 6. Genome editing in the crustacean Daphnia magna using CRISPR/Cas and TALEN systems; 7. Leapfrogging: a method for targeting genome editing to the germline; 8. Genome editing with desired mutations (knock-in) by CRISPR in model organisms; 9. Genetically engineered pig models for human diseases using ZFNs, TALENs and CRISPR-Cas9; 10. Gene editing to create agricultural and biomedical swine models; 11. Generation of new model cell lines using ssODN knock-in donors and FACS-based genome editing; Part III. Technology Development and Screening: 12. CRISPR genome editing in mice; 13. Detection of insertion/deletion (indel) events after genome targeting: pros and cons of the available methods; 14. Application of TAL proteins and the CRISPR system to purification of specific genomic regions for locus-specific identification of chromatin-associated molecules; 15. Application of CRISPR for pooled, vector-based functional genomic screening in mammalian cell lines; 16. Generation and utilization of CRISPR/Cas9 screening libraries in mammalian cells; Part IV. Genome Editing in Stem Cells and Regenerative Biology: 17. Targeted genome editing using nuclease assisted vector integration; 18. Genome engineering using Sleeping Beauty transposition in vertebrates; 19. Genome editing of pluripotent stem cells; 20. Principles for targeting adult tissue stem cells to achieve durable gene and gene-editing therapies; 21. Therapeutic genome editing in human hematopoietic stem and progenitor cells; Part V. Genome Editing in Disease Biology: 22. CRISPR/Cas9-Based in vivo models of cancer; 23. Inducible CRISPR-based genome editing for the characterization of cancer genes; 24. Genome editing for retinal diseases; 25. Manipulation of long non-coding RNAs in cardiovascular disease using genome-editing technology; 26. Gene silencing, disruption and latency reactivation with RNA-based and gene editing CRISPR/Cas, ZFN and TALEN technologies for HIV-1/AIDS therapies; 27. Use of the CRISPR-Cas9 system for genome editing of immune system cells, defense against HIV-1 and cancer therapies; 28. Harnessing therapeutic potential of long non-coding RNAs in immunity; Part VI. Legal (Intelluctual Property) and Bioethical Issues of Genome Editing: 29. Patening of CRISPR-based inventions; 30. Patent, ownership, and licensing issues of CRISPR-based genome editing: impact on universities and their licensees; 31. The ethics of human genome editing; 32. Regulating human genome editing: negotiating ethical concerns through science and policy; Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
